DNA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
27.7M
+37.5%
20.2M
+3.5%
19.5M
-41.7%
33.4M
+13.7%
29.4M
Cost of Revenue
1.8M
+5.1%
1.7M
-44.5%
3.1M
-57.6%
7.3M
+57.9%
4.6M
Gross Profit
25.9M
+40.5%
18.4M
+12.6%
16.4M
-37.2%
26.1M
+5.4%
24.8M
Operating Expenses
69.5M
-9.7%
77.0M
-18.9%
94.9M
-2.0%
96.8M
-9.5%
107.1M
R&D
40.9M
-11.4%
46.2M
-7.4%
49.9M
-0.4%
50.1M
-27.7%
69.4M
SG&A
28.6M
-7.1%
30.8M
-18.6%
37.8M
-17.8%
46.0M
+24.4%
37.0M
Operating Income
-43633000
+25.5%
-58548000
+25.4%
-78521000
-11.0%
-70752000
+14.0%
-82305000
EBITDA
-31595000
+31.7%
-46233000
+29.7%
-65722000
-16.6%
-56383000
+17.0%
-67960000
Net Income
-40984000
+12.3%
-46710000
+43.4%
-82587000
-2.3%
-80751000
+0.0%
-80755000
EPS (Basic)
$-0.64
+14.7%
$-0.75
+46.0%
$-1.39
+1.4%
$-1.41
+2.8%
$-1.45
EPS (Diluted)
$-0.64
+14.7%
$-0.75
+46.0%
$-1.39
+1.4%
$-1.41
+2.8%
$-1.45
Shares (Diluted)
64.0M
+3.0%
62.1M
+4.2%
59.6M
+4.3%
57.1M
+2.6%
55.6M
Ginkgo Bioworks (DNA) — Financials